Core Insights - Chautauqua Capital Management's third-quarter 2025 investor letter indicates that global equity markets performed well due to the resolution of trade conflicts and a dovish shift in U.S. monetary policy [1] - The Baird Chautauqua International Growth Fund and the Baird Chautauqua Global Growth Fund underperformed their respective benchmarks, primarily due to poor stock selection in the information technology, financials, and industrials sectors [1] Company Highlights - BeOne Medicines AG (NASDAQ:ONC) is highlighted as a key stock, reporting a one-month return of -7.71% and a 52-week gain of 64.97% [2] - As of December 30, 2025, BeOne Medicines AG's stock closed at $304.72 per share, with a market capitalization of $33.72 billion [2] - BeOne Medicines AG reported a strong quarter with a revenue of $1.4 billion, reflecting a 41% year-on-year growth, and raised its FY25 guidance [3] - The company is gaining market share with its key product, Brukinsa, and management anticipates positive free cash flow in 2025 [3] - BeOne Medicines AG was held by 21 hedge fund portfolios at the end of Q3 2025, a decrease from 28 in the previous quarter [3]
Strong Momentum Lifted BeOne Medicines AG (ONC) in Q3